Chen Zihan, Yu Jiangnan, Guo Zhikun, Chen Shuxian, Li Yina, Zhou Qian, Wang Lei
International Cancer Center, Shenzhen University Medical School, Shenzhen 518054, Guang Dong, China.
Explor Target Antitumor Ther. 2025 May 13;6:1002315. doi: 10.37349/etat.2025.1002315. eCollection 2025.
With the escalating application of immune checkpoint inhibitors (ICIs) in solid tumors, these therapies have demonstrated clinical benefits but remain hampered by relatively low response rates. Reliable biomarkers to predict ICIs responsiveness are essential for selecting appropriate patients and optimizing therapeutic outcomes. Given the pivotal role of tumor-draining lymph nodes (TDLNs) in orchestrating systemic antitumor immunity, their intrinsic features-such as dynamic organization in T cell subsets and functional status of antigen-presenting cells, hold considerable potential as predictive biomarkers for ICIs. Moreover, the complexity of ICIs-induced responses in TDLNs necessitates integrating multiple biomarkers for accurate prediction. Through continuous refinement of predictive strategies, TDLNs are poised to play an indispensable role in enhancing ICIs efficacy and guiding personalized immunotherapy. Here, we provide a review to discuss the possibility of using the intrinsic features of TDLNs as a predictive marker for ICI therapy.
随着免疫检查点抑制剂（ICIs）在实体瘤中的应用不断增加，这些疗法已显示出临床益处，但仍受限于相对较低的缓解率。预测ICIs反应性的可靠生物标志物对于选择合适的患者和优化治疗结果至关重要。鉴于肿瘤引流淋巴结（TDLNs）在协调全身抗肿瘤免疫中的关键作用，其内在特征，如T细胞亚群的动态组织和抗原呈递细胞的功能状态，作为ICIs的预测生物标志物具有相当大的潜力。此外，ICIs在TDLNs中诱导反应的复杂性需要整合多种生物标志物以进行准确预测。通过不断完善预测策略，TDLNs有望在提高ICIs疗效和指导个性化免疫治疗中发挥不可或缺的作用。在此，我们提供一篇综述，讨论将TDLNs的内在特征用作ICI治疗预测标志物的可能性。
